Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM

Trial ID or NCT#

NCT01912534

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this trial is to determine whether treatment with valsartan will have beneficial effect in early hypertrophic cardiomyopathy (HCM) by assessing many domains that reflect myocardial structure, function and biochemistry.

Official Title

Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM

Eligibility Criteria

Ages Eligible for Study: 8 Years to 45 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Euan A. Ashley
Euan A. Ashley
Cardiologist, Heart failure cardiologist
Associate Dean, School of Medicine, Roger and Joelle Burnell Professor of Genomics and Precision Health, Professor of Medicine (Cardiovascular Medicine), of Genetics, of Biomedical Data Science and, by courtesy, of Pathology

Contact us to find out if this trial is right for you.

CONTACT

Euan Ashley, MD, PhD
(650) 498-4900

View on ClinicalTrials.gov